IL6 and breast carcinoma: This then inhibits NF-κB-dependent production of IL-6, STAT3 activation, and IL-6/STAT3-driven cell migration and invasion of breast cancer cells, thereby establishing an IL-6/STAT3/NF-κB/miR-146a negative feedback loop.